annual total liabilities:
$775.17M+$70.91M(+10.07%)Summary
- As of today (June 28, 2025), PCRX annual total liabilities is $775.17 million, with the most recent change of +$70.91 million (+10.07%) on December 31, 2024.
- During the last 3 years, PCRX annual total liabilities has fallen by -$569.78 million (-42.36%).
- PCRX annual total liabilities is now -42.36% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$788.13M+$12.96M(+1.67%)Summary
- As of today (June 28, 2025), PCRX quarterly total liabilities is $788.13 million, with the most recent change of +$12.96 million (+1.67%) on March 31, 2025.
- Over the past year, PCRX quarterly total liabilities has increased by +$96.97 million (+14.03%).
- PCRX quarterly total liabilities is now -41.40% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PCRX Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.1% | +14.0% |
| 3 y3 years | -42.4% | -33.3% |
| 5 y5 years | +62.8% | +76.2% |
PCRX Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.4% | +10.1% | -33.3% | +14.0% |
| 5 y | 5-year | -42.4% | +62.8% | -41.4% | +76.2% |
| alltime | all time | -42.4% | +1700.6% | -41.4% | +1605.9% |
PCRX Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $788.13M(+1.7%) |
| Dec 2024 | $775.17M(+10.1%) | $775.17M(+0.4%) |
| Sep 2024 | - | $772.11M(+0.6%) |
| Jun 2024 | - | $767.54M(+11.1%) |
| Mar 2024 | - | $691.16M(-1.9%) |
| Dec 2023 | $704.26M(-22.3%) | $704.26M(+0.2%) |
| Sep 2023 | - | $702.91M(-4.3%) |
| Jun 2023 | - | $734.41M(-2.8%) |
| Mar 2023 | - | $755.38M(-16.6%) |
| Dec 2022 | $906.19M(-32.6%) | $906.19M(-6.0%) |
| Sep 2022 | - | $964.24M(-1.3%) |
| Jun 2022 | - | $977.35M(-17.3%) |
| Mar 2022 | - | $1.18B(-12.1%) |
| Dec 2021 | $1.34B(+105.4%) | $1.34B(+111.0%) |
| Sep 2021 | - | $637.40M(-0.2%) |
| Jun 2021 | - | $638.66M(+0.3%) |
| Mar 2021 | - | $636.73M(-2.8%) |
| Dec 2020 | $654.83M(+37.5%) | $654.83M(+3.0%) |
| Sep 2020 | - | $635.58M(+33.0%) |
| Jun 2020 | - | $477.96M(+6.8%) |
| Mar 2020 | - | $447.34M(-6.0%) |
| Dec 2019 | $476.12M(+29.3%) | $476.12M(+3.2%) |
| Sep 2019 | - | $461.33M(+3.4%) |
| Jun 2019 | - | $446.19M(+13.9%) |
| Mar 2019 | - | $391.64M(+6.4%) |
| Dec 2018 | $368.13M(+5.5%) | $368.13M(+2.9%) |
| Sep 2018 | - | $357.78M(+1.6%) |
| Jun 2018 | - | $352.17M(+2.5%) |
| Mar 2018 | - | $343.52M(-1.5%) |
| Dec 2017 | $348.89M | $348.89M(+2.2%) |
| Sep 2017 | - | $341.29M(-1.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $344.70M(+4.7%) |
| Mar 2017 | - | $329.33M(+90.9%) |
| Dec 2016 | $172.49M(+1.9%) | $172.49M(+3.3%) |
| Sep 2016 | - | $167.00M(-3.1%) |
| Jun 2016 | - | $172.35M(+4.4%) |
| Mar 2016 | - | $165.04M(-2.5%) |
| Dec 2015 | $169.34M(+9.3%) | $169.34M(+5.9%) |
| Sep 2015 | - | $159.97M(+0.2%) |
| Jun 2015 | - | $159.71M(+5.8%) |
| Mar 2015 | - | $151.01M(-2.5%) |
| Dec 2014 | $154.93M(+20.5%) | $154.93M(+3.1%) |
| Sep 2014 | - | $150.32M(+4.3%) |
| Jun 2014 | - | $144.11M(+12.6%) |
| Mar 2014 | - | $127.98M(-0.5%) |
| Dec 2013 | $128.57M(+178.3%) | $128.57M(+4.3%) |
| Sep 2013 | - | $123.28M(+3.3%) |
| Jun 2013 | - | $119.29M(+3.3%) |
| Mar 2013 | - | $115.45M(+149.9%) |
| Dec 2012 | $46.20M(-29.2%) | $46.20M(-11.8%) |
| Sep 2012 | - | $52.38M(+8.3%) |
| Jun 2012 | - | $48.35M(-15.2%) |
| Mar 2012 | - | $57.02M(-12.6%) |
| Dec 2011 | $65.22M(-43.3%) | $65.22M(+2.3%) |
| Sep 2011 | - | $63.73M(-0.7%) |
| Jun 2011 | - | $64.16M(-3.8%) |
| Mar 2011 | - | $66.72M(-42.0%) |
| Dec 2010 | $114.94M(+71.8%) | $114.94M(+20.0%) |
| Sep 2010 | - | $95.79M(+13.4%) |
| Jun 2010 | - | $84.47M(+26.3%) |
| Dec 2009 | $66.90M(+55.4%) | $66.90M |
| Dec 2008 | $43.05M | - |
FAQ
- What is Pacira BioSciences annual total liabilities?
- What is the all time high annual total liabilities for Pacira BioSciences?
- What is Pacira BioSciences annual total liabilities year-on-year change?
- What is Pacira BioSciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for Pacira BioSciences?
- What is Pacira BioSciences quarterly total liabilities year-on-year change?
What is Pacira BioSciences annual total liabilities?
The current annual total liabilities of PCRX is $775.17M
What is the all time high annual total liabilities for Pacira BioSciences?
Pacira BioSciences all-time high annual total liabilities is $1.34B
What is Pacira BioSciences annual total liabilities year-on-year change?
Over the past year, PCRX annual total liabilities has changed by +$70.91M (+10.07%)
What is Pacira BioSciences quarterly total liabilities?
The current quarterly total liabilities of PCRX is $788.13M
What is the all time high quarterly total liabilities for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total liabilities is $1.34B
What is Pacira BioSciences quarterly total liabilities year-on-year change?
Over the past year, PCRX quarterly total liabilities has changed by +$96.97M (+14.03%)